Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Candel Therapeutics Inc (NQ: CADL )

4.790 +0.650 (+15.70%)
Streaming Delayed Price Updated: 10:31 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Candel Therapeutics Inc

< Previous 1 2 3 4 5 6 Next >
Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
From Candel Therapeutics
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday saw 59 companies set new 52-week lows. 
Via Benzinga
Candel Therapeutics: Q1 Earnings Insights
Via Benzinga
Candel Therapeutics's Return On Capital Employed Insights
Via Benzinga
Candel Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Why ToughBuilt Industries Shares Are Trading Lower By Over 46%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares jumped 209.5% to $2.29 after the company signed a Letter of Intention with UAE-Based e-script medicine management company Pharmak... 
Via Benzinga
Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors
Nicoletta Loggia, PhD, RPh, biopharma executive with more than two decades of technical expertise in the biopharmaceutical industry 
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Says One Dose Of CAN-3110 Shows Encouraging Responses In A Type Of Brain Cancer
Candel Therapeutics Inc (NASDAQ: CADL) announced new data from an ongoing phase 1 trial of its herpes simplex virus-1 (HSV-1) replication-competent viral immunotherapy candidate, CAN-3110, in patients... 
Via Benzinga
Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO
From Candel Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer
Fast track designation has the potential to facilitate the development and expedite the U.S. FDA review of CAN-2409 plus valacyclovir and anti-PD1 antibodies in patients with stage III/IV non-small... 
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day
From Candel Therapeutics
Via GlobeNewswire
Why Tupperware Brands Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers PLx Pharma Inc. (NASDAQ: PLXP) gained 128.2% to $0.2399 after dropping over 13% on Thursday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference
From Candel Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics to Host Virtual R&D Day on December 6, 2022
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2022
Via Benzinga
Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Upcoming Investor Conference Participation for November
From Candel Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.